Explore

Trendline Trendline
DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress

DiaMedica Therapeutics Reports Q1 2026 Financial Results and Clinical Progress
Trendline Trendline
DiaMedica Therapeutics Reports Financial Results and Clinical Progress for Q1 2026

DiaMedica Therapeutics Reports Financial Results and Clinical Progress for Q1 2026

DiaMedica Therapeutics Reports Financial Results and Clinical Progress for Q1 2026
Trendline Trendline
ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients

ISOThrive Announces Positive Phase 2 Results for MHS-1031 in NERD Patients
Trendline Trendline
Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Pipeline

Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Pipeline

Bayer Acquires Perfuse Therapeutics to Enhance Ophthalmology Pipeline
Trendline Trendline
Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions

Gene Therapy Faces Evidence Challenges Amid FDA Decisions
Trendline Trendline
SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions

SAB Biotherapeutics Enters $36 Million Manufacturing Agreement for SAB-142 with Emergent BioSolutions
Trendline Trendline
Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results

Travere Therapeutics Reports Significant Growth in Q1 2026 Financial Results
Trendline Trendline
Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept

Vertex Pharmaceuticals Prepares for Potential Breakthrough in Renal Treatment with Povetacicept
Trendline Trendline
Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead

Madrigal Pharmaceuticals Acquires siRNA Asset for MASH in $1 Billion Deal with Arrowhead
Trendline Trendline
Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables

Mapi Pharma Plans U.S. Aseptic Manufacturing Facility to Meet Growing Demand for Injectables
Trendline Trendline
Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease

Takeda's TAK-881 Shows Promising Results in Phase 2/3 Trial for Primary Immunodeficiency Disease
Trendline Trendline
FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals

FDA Rejection Highlights Challenges in Gene Therapy Approvals